Briceno Vanessa, Zaidi Hasan A, Doucette Joanne A, Onomichi Kaho B, Alreshidi Amer, Mekary Rania A, Smith Timothy R
a Department of Pharmaceutical Business and Administrative Sciences , MCPHS University , Boston , MA , USA.
b Department of Neurosurgery , Cushing Neurosurgery Outcomes Center, Brigham and Women's Hospital, Harvard Medical School , Boston , MA , USA.
Neurol Res. 2017 May;39(5):387-398. doi: 10.1080/01616412.2017.1296653. Epub 2017 Mar 16.
Growth hormone-secreting pituitary adenomas in adults can result in severe craniofacial disfigurement and potentially fatal medical complications. Surgical resection leading to remission of the disease is dependent on complete surgical resection of the tumor. Lesions that invade the cavernous sinus may not be safely accessible via an endonasal transsphenoidal surgery (TSS), and the rates of biochemical remission of patients with residual disease vary widely in the literature. We conducted a meta-analysis to examine the prevalence of biochemical remission after TSS among patients with growth hormone-secreting pituitary adenomas with and without cavernous sinus invasion.
Embase, PubMed, and Cochrane Library databases were searched for relevant publications. Fourteen studies with 972 patients with biochemically confirmed growth hormone-secreting pituitary adenomas were included in the meta-analysis.
The overall remission prevalence under a fixed-effect model was 47.6% (95% CI = 40.8-54.4%) for patients with invasive macroadenomas (I = 74.6%, p < 0.01); 76.4% (95% CI = 72.2-80.1%) for patients with non-invasive macroadenomas (I = 59.6%, p = 0.03); and 74.2% (95% CI = 66.3-80.7%) for patients with non-invasive microadenomas (I = 36.4, p = 0.10). The significant difference among the three groups resulted from the difference between patients with or without cavernous sinus invasion (p = 0.01) and not from the size of adenomas among those without cavernous sinus invasion (p = 0.66).
The prevalence of biochemical remission in patients with cavernous sinus invasion was lower than in patients without cavernous sinus invasion after TSS for acromegaly.
成人分泌生长激素的垂体腺瘤可导致严重的颅面畸形和潜在的致命医学并发症。手术切除使疾病缓解取决于肿瘤的完全手术切除。侵犯海绵窦的病变可能无法通过鼻内镜经蝶窦手术(TSS)安全切除,且文献中残留疾病患者的生化缓解率差异很大。我们进行了一项荟萃分析,以研究有或无海绵窦侵犯的分泌生长激素的垂体腺瘤患者经TSS后生化缓解的患病率。
检索Embase、PubMed和Cochrane图书馆数据库中的相关出版物。14项研究共972例经生化确诊的分泌生长激素的垂体腺瘤患者纳入荟萃分析。
在固定效应模型下,侵袭性大腺瘤患者的总体缓解患病率为47.6%(95%CI = 40.8 - 54.4%)(I = 74.6%,p < 0.01);非侵袭性大腺瘤患者为76.4%(95%CI = 72.2 - 80.1%)(I = 59.6%,p = 0.03);非侵袭性微腺瘤患者为74.2%(95%CI = 66.3 - 80.7%)(I = 36.4,p = 0.10)。三组之间的显著差异源于有无海绵窦侵犯患者之间的差异(p = 0.01),而非无海绵窦侵犯患者中腺瘤大小的差异(p = 0.66)。
肢端肥大症患者经TSS后,海绵窦侵犯患者的生化缓解患病率低于无海绵窦侵犯患者。